The results of the Turkish Time R&D 500 Survey 2024, one of the most comprehensive R&D studies in Türkiye, have been announced.
We are pleased to share that GEN ranked 74th among the top 500 companies based on R&D expenditure, 6th in the pharmaceutical sector, and 28th in the number of projects carried out at our R&D Centre.
This achievement is a strong indicator of our vision to develop innovative solutions, support scientific research, and shape the treatments of the future today.
We would like to thank all our colleagues who contributed to this success and look forward to achieving many more milestones together.
